Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Pyxis Oncology (PYXS) Net Margin (2024 - 2025)

Pyxis Oncology (PYXS) has 2 years of Net Margin data on record, last reported at 164.16% in Q4 2025.

  • On a quarterly basis, Net Margin changed N/A to 164.16% in Q4 2025 year-over-year; TTM through Dec 2025 was 576.32%, a 8445.0% decrease, with the full-year FY2025 number at 574.65%, down 9570.0% from a year prior.
  • Net Margin reached 164.16% in Q4 2025 per PYXS's latest filing, up from 640.82% in the prior quarter.
  • Over the last five years, Net Margin for PYXS hit a ceiling of 33.09% in Q1 2024 and a floor of 640.82% in Q2 2025.